drugset / Trial / NCT05996848

A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight

NCT05996848

Phase 3 Completed 300 enrolled Novo Nordisk A/S
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will look at how well the new medicine CagriSema helps people with excess body weight losing weight compared to a "dummy" medicine and a medicine called semaglutide. Participants will either get CagriSema, a dummy medicine or semaglutide. Which treatment participants get is decided by chance. Participants will take one injection once a week. The study medicine will be injected briefly with a thin needle, typically in the stomach, thighs or upper arms. The study will last for about 1 year.

Timeline

Start
2023-08-15
Primary completion
2025-01-06
Completion
2025-02-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Cagrilintide Protein / enzyme biologic 2.4 mg Subcutaneous
Subject Semaglutide Peptide 2.4 mg Subcutaneous

Indications